Twist Bioscience Corporation $TWST Shares Purchased by Profund Advisors LLC

Profund Advisors LLC raised its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 71.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,355 shares of the company’s stock after acquiring an additional 17,701 shares during the period. Profund Advisors LLC’s holdings in Twist Bioscience were worth $1,344,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its stake in Twist Bioscience by 11.2% during the fourth quarter. ProShare Advisors LLC now owns 13,636 shares of the company’s stock worth $433,000 after acquiring an additional 1,375 shares during the last quarter. Maxi Investments CY Ltd acquired a new position in shares of Twist Bioscience in the 4th quarter valued at about $1,110,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Twist Bioscience by 11.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 44,668 shares of the company’s stock worth $1,447,000 after purchasing an additional 4,704 shares during the period. SBI Securities Co. Ltd. grew its holdings in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after purchasing an additional 571 shares during the period. Finally, Benjamin Edwards Inc. increased its position in Twist Bioscience by 4.6% during the 4th quarter. Benjamin Edwards Inc. now owns 29,632 shares of the company’s stock worth $940,000 after purchasing an additional 1,309 shares in the last quarter.

Insider Buying and Selling

In other news, Director Robert Chess sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total transaction of $470,000.00. Following the completion of the sale, the director directly owned 21,084 shares in the company, valued at $990,948. This trade represents a 32.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Melissa A. Starovasnik sold 1,000 shares of Twist Bioscience stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total value of $51,000.00. Following the sale, the director directly owned 25,722 shares in the company, valued at approximately $1,311,822. The trade was a 3.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 46,551 shares of company stock worth $2,566,533 over the last quarter. Company insiders own 3.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TWST. Evercore raised their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Robert W. Baird increased their price objective on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Guggenheim raised their target price on shares of Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Barclays lifted their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Finally, Leerink Partners raised shares of Twist Bioscience from a “market perform” rating to an “outperform” rating and set a $70.00 price target for the company in a research report on Tuesday, May 5th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.57.

Twist Bioscience Trading Up 8.4%

TWST opened at $53.66 on Thursday. The firm’s 50 day moving average is $52.03 and its 200-day moving average is $42.95. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $66.06. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $3.34 billion, a P/E ratio of -40.35 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The firm had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. Twist Bioscience’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.66) earnings per share. Analysts expect that Twist Bioscience Corporation will post -1.86 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.